Tonix Pharmaceuticals Holding Corp. has achieved a significant milestone with the FDA’s recent approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Fibromyalgia is a complex chronic condition characterized by widespread musculoskeletal pain, fatigue, and various other symptoms including sleep disturbances and cognitive issues. Tonmya stands out as a non-opioid, once-daily bedtime analgesic featuring a unique sublingual formulation designed for rapid absorption into the bloodstream.
This approval marks a significant advancement in the field, as Tonmya becomes the first new FDA-approved therapy for fibromyalgia in over 15 years. The decision was supported by compelling efficacy data from two Phase 3 clinical trials involving nearly 1,000 patients. Notably, Tonmya demonstrated a significant reduction in daily pain scores compared to a placebo at the 14-week mark, which was the primary endpoint of the trials. Furthermore, a higher proportion of patients treated with Tonmya experienced a clinically meaningful improvement of at least 30% in their pain levels after three months compared to those on placebo.
Across three Phase 3 clinical trials involving over 1,400 patients, Tonmya exhibited a favorable tolerability profile, indicating its potential as a well-tolerated treatment option for fibromyalgia patients. The most recent Phase 3 trial, RESILIENT, published in Pain Medicine, provided comprehensive data on primary and secondary endpoints related to pain levels, patients’ overall impression of change, symptoms and function reported by patients, sleep quality, and fatigue.
Tonmya is anticipated to be commercially available for adult fibromyalgia patients in the U.S. starting in the fourth quarter of this year. With a robust cash position of $125.3 million as of the end of the June quarter and a projected cash runway extending into the third quarter of 2026, Tonix Pharmaceuticals is well-positioned to support the launch and further development of Tonmya.
In contrast to Tonix Pharmaceuticals’ success, another company, Axsome Therapeutics, Inc., faced a setback when the FDA issued a “refusal to file” letter concerning its fibromyalgia treatment, AXS-14 (esreboxetine). The agency determined that the New Drug Application for AXS-14 was not complete enough to undergo a substantive review, highlighting the rigorous standards and scrutiny involved in the drug approval process.
The market response to Tonix Pharmaceuticals’ achievement has been notable, with the company’s stock price rising by over 320% in the last six months. However, recent trading data shows a slight decline in TNXP stock by 8.20% to $47.14, reflecting the dynamic nature of the biopharmaceutical industry and investor sentiment in response to regulatory decisions and product advancements.
Key Takeaways:
– Tonix Pharmaceuticals’ FDA approval of Tonmya for fibromyalgia marks a significant breakthrough in addressing the unmet medical needs of patients with this challenging condition.
– The company’s robust cash position and anticipated cash runway provide a solid foundation for the commercial launch and future development of Tonmya.
– The contrasting outcomes for Tonix Pharmaceuticals and Axsome Therapeutics underscore the rigorous regulatory criteria and uncertainty inherent in the drug approval process.
– Market volatility and investor response demonstrate the dynamic nature of the biopharmaceutical industry, influenced by regulatory decisions, clinical advancements, and competitive landscape shifts.
Tags: clinical trials, formulation
Read more on finance.yahoo.com